MedPath

Can the drug Retinol Palmitate improve dryness and keratinization of the eye in patients with Chronic Stevens Johnson Syndrome

Not Applicable
Completed
Conditions
Health Condition 1: H04- Disorders of lacrimal system
Registration Number
CTRI/2021/11/038155
Lead Sponsor
Dr Rajendra Prasad Centre for Ophthalmic Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
24
Inclusion Criteria

Patients with severe dry eye and ocular surface keratinization in chronic Stevens-Johnson Syndrome

Patients willing to give consent

Exclusion Criteria

Age <18 years

Pregnancy

Presence of other ocular co-morbidities

Patients not willing to follow up

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Visual acuity <br/ ><br>Anterior and posterior segment examination <br/ ><br>Tear film breakup time <br/ ><br>Schirmers test <br/ ><br>Tear film height (ASOCT) <br/ ><br>Epithelial Mapping on ASOCT (Rtvue) <br/ ><br>Impression cytology for conjunctival goblet cell density, conjunctival keratinization, corneal keratinization <br/ ><br>Tear film TGF beta and MMP-9Timepoint: Pre- treatment <br/ ><br>1 week <br/ ><br>2 weeks <br/ ><br>4 weeks <br/ ><br>8 weeks <br/ ><br>12 weeks <br/ ><br>(Impression cytology for conjunctival goblet cell density, conjunctival keratinisation, corneal keratinisation; and Tear film TGF beta and MMP-9 will be performed pre treatment, 1 week, 4 weeks and 12 weeks only)
Secondary Outcome Measures
NameTimeMethod
OSDI QuestionnaireTimepoint: Pre- treatment <br/ ><br>1 week <br/ ><br>2 weeks <br/ ><br>4 weeks <br/ ><br>8 weeks <br/ ><br>12 weeks
© Copyright 2025. All Rights Reserved by MedPath